Point72 Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,183,918
| Closed | -$168M | – | 3977 |
|
|
2026
Q1 | $168M | Buy |
4,183,918
+3,586,246
| +600% | +$77.3M | 0.22% | 74 |
|
|
2025
Q4 | $15M | Buy |
597,672
+380,601
| +175% | +$8.93M | 0.02% | 1094 |
|
|
2025
Q3 | $4.91M | Buy |
+217,071
| New | +$5.06M | 0.01% | 1075 |
|
|
2025
Q1 | – | Sell |
-1,267,958
| Closed | -$40.5M | – | 2023 |
|
|
2024
Q4 | $40.5M | Buy |
+1,267,958
| New | +$38.1M | 0.09% | 264 |
|
|
2024
Q2 | – | Sell |
-267,823
| Closed | -$15.7M | – | 1841 |
|
|
2024
Q1 | $15.7M | Buy |
+267,823
| New | +$17.1M | 0.04% | 543 |
|
|
2023
Q3 | – | Sell |
-1,239,361
| Closed | -$113M | – | 2442 |
|
|
2023
Q2 | $113M | Sell |
1,239,361
-640,363
| -34% | -$55.3M | 0.34% | 66 |
|
|
2023
Q1 | $124M | Buy |
+1,879,724
| New | +$108M | 0.38% | 53 |
|
|
2021
Q2 | – | Sell |
-250,000
| Closed | -$10.7M | – | 960 |
|
|
2021
Q1 | $10.7M | Buy |
250,000
+226,600
| +968% | +$10.7M | 0.05% | 411 |
|
|
2020
Q4 | $1.34M | Sell |
23,400
-423,536
| -95% | -$17.9M | 0.01% | 781 |
|
|
2020
Q3 | $13.5M | Buy |
446,936
+238,833
| +115% | +$7.14M | 0.07% | 344 |
|
|
2020
Q2 | $6.8M | Sell |
208,103
-112,198
| -35% | -$3.6M | 0.04% | 421 |
|
|
2020
Q1 | $8.58M | Buy |
+320,301
| New | +$11.4M | 0.07% | 320 |
|
|
2019
Q3 | – | Sell |
-401,104
| Closed | -$10.2M | – | 1126 |
|
|
2019
Q2 | $10.2M | Buy |
401,104
+67,475
| +20% | +$1.37M | 0.05% | 378 |
|
|
2019
Q1 | $6.51M | Buy |
333,629
+222,613
| +201% | +$3.5M | 0.03% | 502 |
|
|
2018
Q4 | $1.46M | Buy |
+111,016
| New | +$1.7M | 0.01% | 762 |
|
Other funds holding APLS
Point72 Asset Management's APLS Position: Q2 2026 in Review
Point72 Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 4,183,918 shares — an estimated $168M sold.
Point72 Asset Management first reported a position in APLS in Q4 2018 and held it in 15 quarters. The position peaked at $168M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Point72 Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Point72 Asset Management sold 4,183,918 Apellis Pharmaceuticals shares in Q2 2026, an estimated $168M.
- Point72 Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 15 quarters.
- Point72 Asset Management's Apellis Pharmaceuticals position peaked at $168M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.